Edwards Lifesciences (NYSE:EW) Issues FY25 Earnings Guidance

Edwards Lifesciences (NYSE:EW) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided EPS guidance of $2.40-2.50 for the period, compared to the consensus EPS estimate of $2.45. The company issued revenue guidance of $5.6-6.0 billion. Edwards Lifesciences also updated its FY 2025 guidance to 2.400-2.500 EPS.

Edwards Lifesciences Stock Up 5.7 %

Shares of NYSE EW opened at $74.21 on Thursday. The company has a market capitalization of $43.77 billion, a price-to-earnings ratio of 10.71, a price-to-earnings-growth ratio of 3.95 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The business has a 50-day moving average of $68.42 and a two-hundred day moving average of $74.77. Edwards Lifesciences has a 1 year low of $58.93 and a 1 year high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter in the previous year, the firm earned $0.59 earnings per share. The business’s revenue was up 8.9% compared to the same quarter last year. On average, analysts forecast that Edwards Lifesciences will post 2.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Oppenheimer restated an “outperform” rating and issued a $90.00 price target on shares of Edwards Lifesciences in a research report on Thursday, September 12th. Robert W. Baird dropped their price target on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. JPMorgan Chase & Co. boosted their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Jefferies Financial Group cut Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their price target for the company from $85.00 to $70.00 in a research report on Wednesday, September 18th. Finally, Piper Sandler dropped their price target on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Seventeen equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Hold” and an average target price of $77.50.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. This represents a 9.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Larry L. Wood sold 25,000 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now directly owns 198,526 shares in the company, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 40,000 shares of company stock valued at $2,657,000. 1.29% of the stock is owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.